Table 4.
Odds ratios of CAN by a 50% higher level of serum and urine collagen markers
| Model 1 | Model 2 | Model 3 | |
|---|---|---|---|
| Odds ratio of CAN | |||
| Serum PRO-C6 (ng/ml) | 2.13 (1.05;4.30) [0.032] | 2.68 (1.12;6.44) [0.02] | 2.53 (1.06;6.04) [0.030] |
| Serum C3M (ng/ml) | 1.66 (0;77;3.55) [0.193] | 2.08 (0.82;5.25) [0.125] | 1.92 (0.74;4.97) [0.185] |
| Urine PRO-C6 (ng/µmol) | 0.12 (0.00;41.90) [0.459] | 0.01 (0.00;143.05) [0.297] | 0.00 (0.00;50.35) [0.197] |
| Urine C3M (ng/µmol) | 0.98 (0.43;1.16) [0.940] | 0.83 (0.46;1.50) [0.534] | 0.86 (0.48;1.57) [0.632] |
Estimates of linear logistic regression models presented as odds ratios (95% confidence intervals, P-values) of CAN or DSPN as a function of a 50% increase in determinants: Model 1 adjusted for age and sex, Model 2 further adjusted for diabetes duration, HbA1c, BMI, smoking, systolic blood pressure, LDL cholesterol and beta blocker treatment (only for CAN), Model 3 additionally adjusted for eGFR. CAN: cardiovascular autonomic neuropathy; DSPN: distal symmetrical polyneuropathy; PRO-C6: Collagen type VI (COL6) and C3M III: Collagen type (COL3)